A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Executive Summary
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.
You may also be interested in...
CMS Reviewing Aprepitant NCD To Add Use With Moderately Emetogenic Chemo
The current Medicare Part B national coverage determination says use of the anti-nausea drug with highly emetogenic anti-cancer chemotherapy is reasonable and necessary; the National Comprehensive Cancer Network asks CMS to update the NCD based on evidence supporting use with moderately emetogenic agents.
CER Has Been A Part Of CMS Coverage Decisions In Recent Years – Avalere
During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions. But CER has already been considered in making Medicare coverage decisions for years, recent Avalere Health analysis of national coverage determinations issued by CMS points out.
CER Has Been A Part Of CMS Coverage Decisions In Recent Years – Avalere
During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions. But CER has already been considered in making Medicare coverage decisions for years, recent Avalere Health analysis of national coverage determinations issued by CMS points out.